HighTide Therapeutics

It was a great week in the Big Apple, where HighTide CEO Liping Liu joined more than 200 fellow leaders and entrepreneurs at the Johnson & Johnson Innovation JLABS 2024 Global CEO Summit. The event featured fireside chats, an innovation showcase, and a trip to #NYSE. #JLABSCEOSummit

🗓️ Heading to next month's American Association for the Study of Liver Diseases (AASLD) 𝗟𝗶𝘃𝗲𝗿 𝗠𝗲𝗲𝘁𝗶𝗻𝗴? We'll be presenting post-hoc analyses of the Phase 2a clinical study of oral berberine ursodeoxycholate (HTD1801), our gut-liver anti-inflammatory metabolic modulator, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and co-morbid type 2 diabetes mellitus (T2DM). The presentations include a comparison of ongoing GLP-1 receptor agonist use with newly initiated HTD1801 treatment, as well as an analysis of the GI tolerance over time to ascertain HTD1801's potential use for long-term management of chronic metabolic conditions such as MASH and T2DM. #MASH #diabetes #liverdisease #metabolicdisease #obesity #gastrointestinal #GI #drugdevelopment #TLM24 #LiverMeeting

Join HighTide at the H.C. Wainwright & Co., LLC 8th Annual MASH Investor Conference next Monday, Oct. 7, to hear the latest from Chief Development Officer Leigh MacConell about our development of multifunctional, multi-targeted therapies for chronic liver & metabolic diseases. The company will also be participating in virtual one-on-one investor meetings. 📺 Register: https://lnkd.in/eJkAPSm8 #metabolicdisease #liverdisease #pharma #drugdevelopment #HCWainwright2024 #MASH

✴️ HighTide Therapeutics is proud to present at the 𝟴𝘁𝗵 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗔𝗦𝗛 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘂𝗺𝗺𝗶𝘁. Don’t miss Alex Liberman’s Thursday talk as he discusses the holistic benefits of berberine ursodeoxycholate in treating #MASH & metabolic diseases. 𝗙𝘂𝗿𝘁𝗵𝗲𝗿 𝗥𝗮𝘁𝗶𝗼𝗻𝗮𝗹𝗲𝘀 𝗳𝗼𝗿 𝗛𝗼𝗹𝗶𝘀𝘁𝗶𝗰 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝘁𝗼 𝗧𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗠𝗔𝗦𝗛 𝗮𝗻𝗱 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝘖𝘳𝘢𝘭 𝘗𝘳𝘦𝘴𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯  🗓️ September 26, 1:45 PM EDT • Brief overview of epidemiology and risk factors in MASH and metabolic diseases, including the added risks when multiple metabolic diseases are present • Preliminary benefits observed in metabolic and hepatic endpoints in Phase 2 studies of berberine ursodeoxycholate (HTD1801) #HTD1801 #metabolicdisease #liverdisease #pharma #drugdevelopment 

What a great #EASD2024 experience! Thanks to all who attended or tuned in to our two oral presentations. We were excited to share the latest promising data about berberine ursodeoxcyholate (HTD1801), and to hear from other attendees. Learn more about what we presented: https://lnkd.in/ewGteRZb #EASD #liverdisease #diabetes #metabolicdisorders #pharma

📣 #𝗘𝗔𝗦𝗗𝟮𝟬𝟮𝟰 𝗡𝗘𝗪𝗦 : Join us for two oral presentations, where we will share post-hoc analyses of clinical studies of our gut-liver anti-inflammatory metabolic modulator berberine ursodeoxcyholate (HTD1801). Learn how it performed in two Phase 2 studies as a multifuctional therapy for those with Type 2 #diabetes, as well as in those with additional metabolic conditions, including #MASH and severe insulin resistance. “𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗼𝗳 𝗕𝗲𝗿𝗯𝗲𝗿𝗶𝗻𝗲 𝗨𝗿𝘀𝗼𝗱𝗲𝗼𝘅𝘆𝗰𝗵𝗼𝗹𝗮𝘁𝗲 (𝗛𝗧𝗗𝟭𝟴𝟬𝟭) 𝗶𝗻 𝗖𝗵𝗶𝗻𝗲𝘀𝗲 𝗮𝗻𝗱 𝗪𝗲𝘀𝘁𝗲𝗿𝗻 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗧𝟮𝗗𝗠” 𝘖𝘳𝘢𝘭 𝘗𝘳𝘦𝘴𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 711 🕐 Wednesday, September 11, 12:45 PM CEST “𝗕𝗲𝗿𝗯𝗲𝗿𝗶𝗻𝗲 𝗨𝗿𝘀𝗼𝗱𝗲𝗼𝘅𝘆𝗰𝗵𝗼𝗹𝗮𝘁𝗲 (𝗛𝗧𝗗𝟭𝟴𝟬𝟭) 𝗣𝗿𝗼𝘃𝗶𝗱𝗲𝘀 𝗮 𝗨𝗻𝗶𝗾𝘂𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝗳𝗼𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝗠𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗮𝗻𝗱 𝗦𝗲𝘃𝗲𝗿𝗲 𝗜𝗻𝘀𝘂𝗹𝗶𝗻 𝗥𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲”  𝘖𝘳𝘢𝘭 𝘗𝘳𝘦𝘴𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 708 🕐 Wednesday, September 11, 12:45 PM CEST #liverdisease #metabolicdisorder #pharma #clinicaltrials #drugdevelopment

Join HighTide at the H.C. Wainwright 26th Annual Global Investment Conference Sept. 9-11, to hear the latest from Chief Development Officer Leigh MacConell about our development of multifunctional, multi-targeted therapies for chronic liver & metabolic diseases. The company will also be participating in investor meetings. 📺 Register to watch the webcast (starting 7am EDT on Sept. 9 and available for 90 days): https://lnkd.in/eU_MevYx #metabolicdisease #liverdisease #pharma #drugdevelopment #HCWainwright

ENROLLMENT COMPLETE: Our two Phase III clinical trials testing berberine ursodeoxycholate (HTD1801) in patients with type 2 #diabetes have completed enrollment. Both trials are evaluating our first-in-class gut-liver anti-inflammatory metabolic modulator for its effects on HbA1c and other indicators of glucose metabolism, lipids, markers of liver injury/function, and inflammation in patients with #T2DM; the first (SYMPHONY-1/NCT06350890) in patients who have poor glycemic control after dietary and exercise interventions, and the second (SYMPHONY-2/NCT06353347) in patients whose diabetes is inadequately controlled with metformin. Thank you to our team and all participants in these important studies. https://ow.ly/VlBV50SoYQ7 $2511HK #metabolicdisorders #pharma #clinicaltrials #drugdevelopment

📢 NEWS FROM #ADASciSessions: 12 weeks of treatment with our gut-liver anti-inflammatory metabolic modulator berberine ursodeoxcycholate (HTD1801) led to significant improvements in glycemic and cardiometabolic health in Type 2 #diabetes patients, regardless of baseline disease severity. As presented today at the American Diabetes Association 84th Scientific Sessions, the post-hoc analysis evaluated the effectiveness of HTD1801 in patients with #T2DM across the disease spectrum based on baseline HbA1c, with a particular emphasis on glycemic and lipid metabolism markers, along with indicators of liver injury. Based on the successful Phase 2 study, two Phase 3 studies (NCT06350890, NCT06353347) are currently ongoing to further evaluate the efficacy and safety of HTD1801 (as monotherapy and as add-on to metformin) in patients with T2DM and inadequate control. 📚 Learn more about the Phase 2 study analysis: https://ow.ly/mVSa50Sna0U 🔎 Visit our active trials: https://ow.ly/FFFP50Sna0V #HTD1801 #liverdisease #metabolicdisorders #pharma #clinicalstudies

We're excited to share the promising results of our Phase 2 study on berberine ursodeoxcycholate (HTD1801) at the #ADASciSessions! Significant improvements in glycemic and cardiometabolic health were observed in Type 2 #diabetes patients across the disease spectrum. Visit our Sunday poster session or stay tuned for details of the findings. #T2DM #HTD1801 #liverdisease #metabolicdisorders #pharma #clinicalstudies American Diabetes Association